“I see no reason as a healthcare provider to intentionally go back and forth needlessly, but I see no concerns that, if I do that, bad things would happen,” said Jason Schairer, MD.
In an interview with The Center for Biosimilars®, Jason Schairer, MD, a gastroenterologist practicing in the Henry Ford Health System in Michigan who specializes in treating patients with inflammatory bowel disease, said that he has seen biosimilars begin to make inroads into clinical practice.
“In our practice,” he said, biosimilars “have slowly been increasing uptake based on provider preference, based on insurance company preference, and based on pharmacy preference to the point where many of our patients are currently receiving biosimilar [anti—tumor necrosis factor] therapy.”
Patients who are naïve to a given agent have had no qualms about starting treatment with a biosimilar rather than a reference product, he reports, although patients who are well maintained on a reference product are sometimes apprehensive, and that requires educating the patient about the data on switching.
Patients in Schairer’s practice who have switched to a biosimilar have not experienced any clinical differences in their treatment thus far, and Schairer points out that some of his patients have had to switch their therapy back and forth multiple times.
“A couple different things are coming together,” he said. “The first is that the individual insurance may mandate medication or the other. In addition, the insurer may now currently recommend that we don’t do our infusions in our office but rather in a third-party infusion center, and that infusion center may have their own pharmacy that has their own preference,” so patients may have switched from a first medication to a second in the practice’s own setting, then back to the first medication in the infusion center setting.
Despite the fact that no biosimilars are yet designated interchangeable by the FDA, says Schairer, “I think the data from Europe support that it should be safe and reasonable, and clinically I’ve seen no problems” in undertaking multiple switches. The primary problem with multiple switches is that it can be frustrating for patients and require additional paperwork for providers.
“I see no reason as a healthcare provider to intentionally go back and forth needlessly, but I see no concerns that, if I do that, bad things would happen.”
Schairer explained that he has spoken with many fellow providers from around the country who have reached out about insurers’ mandates that patients switch treatments. “They have their own anxieties and worries about that process. Now, I don’t share most of their anxieties, but I appreciate that it’s very concerning when you’re used to something that’s been working.”
In counseling his peers on the process of switching patients, he said, “We reference the NOR-SWITCH trial, we reference the Italian data, the Korean data. In general, people have not lost response and, for the most part, have not had increased side effects. I just tell them that, if it’s going to save our patients money, I’m okay with it, but I do hope that insurers are passing savings on to the patients.”
Whether those savings are indeed passed along is an open question; Schairer says that, so far, patients have not yet told him about saving money by switching to a biosimilar. Instead, they have told him that their costs will rise if they fail to make the switch. While biosimilars may be providing savings for the healthcare system as a whole, “I can’t really say [patients] are being factored into the decision.”
Schairer discloses speaking on biosimilars at events sponsored by Pfizer.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Risk-Adjusted NPV Framework for Biosimilars Shows Key Investment Drivers
April 7th 2025Early market entry, manufacturing efficiency, and market share are critical to biosimilar development success, while technical complexity and competition heavily impact returns, according to a study presenting a risk-adjusted net present value (NPV) analysis framework.